Introduction
============

Kaposi\'s sarcoma (KS) is an angioproliferative disorder, the onset of which requires infection with human herpes virus 8 (HHV-8) ([@B1]). There are four presentations in which KS occurs: 1) the classic form, which typically presents in elderly persons of Mediterranean or Eastern European descent; 2) the endemic form, which has been described in indigenous peoples of Sub-Saharan Africa; 3) the iatrogenic form, which is associated with immunosuppressive drug therapy; and 4) the AIDS-associated form ([@B2]). The most common presentation is the AIDS-associated form ([@B3]), and iatrogenic KS is relatively rare. Steroids are the most widely used form of immunosuppressive therapy, but the typical background, management, and prognosis of patients with steroid-induced KS remain unknown. Furthermore, the management of steroid-induced KS may differ from that of other types of KS.

We herein report a case of gastrointestinal (GI)-KS who had received long-term steroid therapy for granulomatosis with polyangiitis. We also conducted a literature review of steroid-induced KS.

Case Report
===========

The patient, a 73-year-old Mongolian man, had been diagnosed with granulomatosis with polyangiitis 1 year earlier. His treatment regimen consisted of high-dose cyclophosphamide 1,000 mg/month and systemic corticosteroids, intravenous methylprednisolone pulse followed by oral prednisolone 50 mg/day ([Fig. 1](#g001){ref-type="fig"}). Remission was achieved, and cyclophosphamide was changed to azathioprine 50 mg/day, with prednisolone slowly tapered to 12 mg/day over 11 months ([Fig. 1](#g001){ref-type="fig"}).

![The clinical course with medication history.](1349-7235-59-0625-g001){#g001}

After 11 months of therapy, he was hospitalized for tarry stool. He had taken lansoprazole daily for 11 months and was not taking any nonsteroidal anti-inflammatory drugs (NSAIDs). On his initial presentation, his vital signs were stable, and gastrointestinal, cardiovascular, pulmonary, skin, and extremities examinations were normal. An HIV-RNA test, cytoplasmic-antineutrophil cytoplasmic antibody, and *Helicobacter pylori* antibody were negative. His hemoglobin concentration was 6.0 g/dL, so he received 6 units of red blood cell transfusion. The hemoglobin concentration then increased to 7.9 g/dL the next day and showed gradual improvement ([Fig. 1](#g001){ref-type="fig"}).

Upper and lower GI endoscopy showed multiple bright-reddish protruding lesions with ulcers ([Fig. 2](#g002){ref-type="fig"}). We found a total of 10 lesions in the stomach and 16 in the colon. No active bleeding was observed from any of the lesions. A biopsy of the lesions revealed the presence of proliferating spindle cells with vascular channels filled with blood cells on Hematoxylin and Eosin (H&E) staining ([Fig. 3A](#g003){ref-type="fig"}). Immunohistochemical staining revealed the expression of the lymphatic vessel endothelial cell marker D2-40 ([Fig. 3B](#g003){ref-type="fig"}) and the blood vessel endothelial cell marker CD34 ([Fig. 3C](#g003){ref-type="fig"}). Some endothelial cells were also positive for HHV-8 LANA-1 ([Fig. 3D](#g003){ref-type="fig"}).

![Endoscopic findings of upper and lower GI tract. A: Multiple reddish, flat lesions in the upper body of the stomach. B: Submucosal tumor-like lesion in the lower body of the stomach. C: Submucosal tumor-like lesion with ulceration in the antrum of the stomach. D: Reddish polypoid lesion in the descending colon. E: Submucosal tumor-like lesion with central ulcer in the sigmoid colon. F: Reddish submucosal tumor-like lesion in the ascending colon.](1349-7235-59-0625-g002){#g002}

![Histological findings of the biopsy specimen from the stomach. A: Low-power view showing a distinct proliferative lesion on Hematoxylin and Eosin staining and high-power view showing spindle cell proliferation with vascular channel formations filled with blood cells (×100, ×200). C: The vascular gaps are lined with endothelial cells when stained with D2-40 (×100). D: The vascular gaps are lined with endothelial cells when stained with CD34 (×100). E: Some endothelial cells are positive for HHV-8 (×100).](1349-7235-59-0625-g003){#g003}

A diagnosis of GI-KS was made based on the endoscopic and pathological findings. We considered that the development of GI-KS was associated with immunosuppression induced by steroid use and initiated treatment by withdrawal of prednisolone. Over the next 4 months, prednisolone was tapered to 6 mg/day. At five months after the diagnosis of GI-KS, repeat upper GI endoscopy showed that the ulcers and reddish lesions had become smaller, and marked improvement was noted after 13 months ([Fig. 4](#g004){ref-type="fig"}). No clinical recurrence occurred during two years of follow-up.

![Changes in upper gastrointestinal endoscopic findings after treatment. A: Reddish flat lesions in the upper body of the stomach. B: Submucosal tumor (SMT) -like lesion in the lower body of the stomach. C: Gastric mucosa in the upper body of the stomach at 13 months after the diagnosis. D: Gastric mucosa in the lower body of the stomach at 13 months after the diagnosis.](1349-7235-59-0625-g004){#g004}

Discussion
==========

We identified several important clinical features in the present case. First, GI-KS can occur in isolation. KS manifests primarily as a cutaneous disorder, with visceral involvement ([@B4]). Nagata et al. reported that 75.8% of AIDS-associated GI-KS patient had cutaneous KS ([@B5]). Iatrogenic GI-KS without cutaneous lesions is considered rare. Second, GI-KS lesions were found in the esophagus, colon, and rectum, which was consistent with findings from a previous study ([@B5],[@B6]). Nagata et al. reported that GI-KS involvement was frequently found in the stomach, duodenum, colon, esophagus, and rectum, in order of increasing frequency ([@B5]), whereas Viazis et al. reported that GI-KS involvement was rarely found in the small intestine ([@B6]). We did not perform small intestinal endoscopy due to the invasiveness of the procedure and because an examination of the small intestine would not have altered the management or treatment in this case. Third, previous studies have shown distinctive endoscopic findings of GI-KS, such as reddish patches, a polypoid appearance, submucosal tumor-like lesions, and ulcerative submucosal tumor ([@B7]), which were detected in our case and facilitated the diagnosis. Fourth, a biopsy of the stomach revealed the presence of proliferating spindle cells with vascular channels filled with red blood cells on H&E staining ([Fig. 3A](#g003){ref-type="fig"}), which is pathologically characteristic of KS ([@B8]). This is seen as reddish mucosa on endoscopy ([Fig. 2](#g002){ref-type="fig"}). We believe that the abundance of red blood cells indicated a small amount of continuous bleeding, which in turn led to the severe anemia. Fifth, GI-KS was induced by steroid use, which is a particularly important feature of this case.

The characteristics, management, and prognosis of patients with steroid-induced KS remain unknown; thus, we reviewed the English-language literature in the MEDLINE database by searching with keywords "Kaposi\'s sarcoma", "steroid", and "immunosuppression". We excluded HIV-positive patients and post-transplantation patients and eventually identified 33 cases of iatrogenic KS due to systemic corticosteroid use (22 men, 11 women; mean age 56 years old, range 7-84 years old) ([Table](#t001){ref-type="table"}) ([@B9]-[@B41]). The underlying diseases included autoimmune disorders such as pemphigus vulgaris, bullous pemphigoid, rheumatoid arthritis, Behçet\'s disease, ulcerative colitis, and Crohn\'s disease. KS most frequently developed on the skin in 26 cases, followed by the GI tract in 11 cases. Of the 11 GI cases, isolated GI-KS accounted for 6 cases, all of which had ulcerative colitis or Crohn\'s disease. The most commonly used steroid was prednisolone, and the amount of steroid used ranged from 2.5 to 80 mg/day. In 20 of 33 cases, discontinuation or tapering of the steroid dose was selected for treatment. Of these 20 cases, 14 (70%) showed improvement, while 6 (30%) did not. In our case, isolated GI-KS was induced by prednisolone that was being administered for the treatment of granulomatosis with polyangiitis. This is the first case of isolated GI-KS without inflammatory bowel disease. GI-KS was improved by tapering prednisolone to 6 mg/day.

###### 

Summary of 33 Cases of Steroid-induced Kaposi's Sarcoma.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.   Reference   Age (y)   Sex   Underlying disease              Lesion             Immunosuppressive drug                     Treatment                                         Outcome
  ----- ----------- --------- ----- ------------------------------- ------------------ ------------------------------------------ ------------------------------------------------- -------------------------------------------
  1     \(9\)       49        M     UC                              Colon\             PSL (15-30 mg/d)\                          Surgery                                           Improvement
                                                                    Rectum             AZA                                                                                          

  2     \(10\)      48        M     UC                              Rectum             Steroid AZA                                Discontinuation of steroid                        No improvement\
                                                                                                                                                                                    Surgery

  3     \(11\)      69        F     MM                              Skin               DEX\                                       Tapering of DEX Discontinuation of BOR and CPA\   Improvement
                                                                                       CPA\                                       Initiation of lenalidomide                        
                                                                                       BOR                                                                                          

  4     \(12\)      36        M     PV                              Skin/Liver\        PSL (60 mg/d)\                             Tapering of PSL (40 mg/d)\                        No improvement\
                                                                    Lung               AZA (100 mg/d)                             Discontinuation of AZA                            Initiation of vinblastine

  5     \(13\)      66        F     GPA                             Skin               PSL (25 mg/d)\                             Tapering of PSL (8 mg/d)\                         No improvement\
                                                                                       CPA                                        Discontinuation of CPA                            Initiation of doxorubicin

  6     \(14\)      84        M     DLBCL                           Skin               R-CHOP (PSL 40 mg/m^2^)                    Surgery                                           Improvement

  7     \(15\)      49        M     RA                              Skin               PSL (15 mg/day)\                           Discontinuation of MTX and PSL\                   No improvement\
                                                                                       MTX (17.5 mg/week)                         Initiation of sirolimus                           Surgery

  8     \(16\)      68        F     BP                              Skin\              PSL (1.0 mg/kg/d)\                         Tapering of PSL (0.5 mg/kg/d)\                    Improvement
                                                                    Lung               AZA (1.5 mg/kg/d)                          Initiation of PTX (240 mg/w)                      

  9     \(17\)      60        M     PV                              Skin               PSL (22.5 mg/d)\                           Tapering of PSL (15 mg/d)\                        Improvement
                                                                                       Mycophenolate mofetil                      Initiation of PTX (270 mg/d)                      

  10    \(18\)      54        M     CD                              Skin               Steroid (20 mg/d)\                         Discontinuation of steroid and AZA                Improvement
                                                                                       AZA (150 mg/d)                                                                               

  11    \(19\)      30        M     UC                              Colon              Steroid                                    Surgery                                           Improvement

  12    \(20\)      30        M     Membranous glomerulonephritis   Oral cavity        PSL (30 mg/d)\                             Discontinuation of PSL and CPA                    Improvement
                                                                                       CPA (200 mg/d)                                                                               

  13    \(21\)      65        M     Knee pain                       Skin\              Steroid (5-40 mg/d)                        Discontinuation of steroid\                       Improvement
                                                                    Oral cavity                                                   Initiation of doxorubicin                         

  14    \(22\)      57        F     RA                              Skin\              Triamcinolone (4 mg/d)\                    Initiation of PTX                                 Improvement
                                                                    Stomach            Leflunomide                                                                                  

  15    \(23\)      7         F     Atopic dermatitis               Skin               Occasional low doses of systemic steroid   Radiotherapy                                      Improvement

  16    \(24\)      65        M     UC Spondylo-arthropathy         Skin\              PSL (5 mg/d)                               Surgery                                           Improvement
                                                                    Colon                                                                                                           

  17    \(25\)      58        M     ITP                             Skin               PSL (80 mg/d)                              Tapering of PSL (10 mg/d)\                        Improvement
                                                                                                                                  Initiation of etoposide                           

  18    \(26\)      57        F     PV                              Skin\              PSL/Ciclosporin\                           Tapering of PSL                                   Improvement
                                                                    Oral cavity        Mycophenolate mofetil                                                                        

  19    \(27\)      62        M     UC                              Small intestine\   Steroid (15 mg/d)\                         Tapering of steroid\                              Improvement
                                                                    Colon              AZA (100 mg/d)                             Discontinuation of AZA                            

  20    \(28\)      43        M     UC                              Colon              PSL Mesalamine                             Surgery                                           Improvement

  21    \(29\)      75        F     Dermato-myositis                Skin               PSL\                                       Tapering of PSL (12.5 mg/d)\                      No improvement\
                                                                                       CPA (0.75 mg/kg/d)                         Monthly IVIg\                                     Initiation of vinblastine and vincristine
                                                                                                                                  Discontinuation of CPA                            

  22    \(30\)      70        M     PV                              Skin               PSL (30 mg/d)\                             PSL (100 mg/day)\                                 No improvement Surgery
                                                                                       AZA\                                       IVIg\                                             
                                                                                       Mycophenolate mofetil                      Topical steroid                                   

  23    \(31\)      49        M     UC                              Skin\              Steroid                                    Surgery\                                          Improvement
                                                                    Colon                                                         Discontinuation of steroid                        

  24    \(32\)      46        M     GPA                             Skin               Steroid (high dose)\                       None                                              Died
                                                                                       AZA·CPA                                                                                      

  25    \(33\)      49        F     ATP                             Skin               PSL (16 mg/d)                              Discontinuation of PSL                            Improvement

  26    \(34\)      68        M     ITP                             Skin               PSL (15 mg/d)                              Discontinuation of PSL                            Improvement

  27    \(35\)      54        M     GPA                             Skin               PSL (50 mg/d)\                             Tapering of PSL and CPA                           Improvement
                                                                                       CPA (100 mg/d)                                                                               

  28    \(36\)      87        F     BP                              Skin               PSL                                        Tapering of PSL (30 mg/d)                         Died

  29    \(37\)      67        F     CD                              Small intestine\   PSL (10 mg/d)                              Surgery                                           Improvement
                                                                    Colon                                                                                                           

  30    \(38\)      29        M     Behçet's disease                Skin/Lung\         PSL (50 mg/d)\                             Discontinuation of CYA and AZA\                   Improvement
                                                                    Stomach\           CYA (5 mg/kg/d)\                           Initiation of interferon                          
                                                                    Duodenum           AZA (150 mg/d)                                                                               

  31    \(39\)      59        M     Focal glomerulosclerosis        Skin\              CPA (100 mg/d)\                            Discontinuation of CPA\                           Improvement
                                                                    Stomach\           PSL(1 mg/kg/d)                             Initiation of vinblastine                         
                                                                    Colon                                                                                                           

  32    \(40\)      72        M     Temporal arteritis              Skin               PSL (25 mg/d)                              Tapering of PSL (5 mg/d)\                         Improvement
                                                                                                                                  Radiation                                         

  33    \(41\)      78        F     Chronic respiratory failure     Skin               PSL (2.5 mg/d)                             Declined all treatment                            Improvement

        our case    73        M     GPA                             Stomach\           PSL (12 mg/d)\                             Tapering of PSL (6 mg/d)                          Improvement
                                                                    Colon              AZA (50 mg/day)                                                                              
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ATP: autoimmune thrombocytopenic purpura, AZA: azathioprine, BOR: bortezomib, BP: bullous pemphigoid, CD: Crohn's disease, CPA: cyclophosphamide, CYA: cyclosporin, DEX: dexamethasone, DLBCL: diffuse large B-cell lymphoma, GPA: granulomatosis with polyangiitis, IVIg: intravenous immunoglobulin, ITP: idiopathic thrombocytopenic purpura, MM: multiple myeloma, MTX: methotrexate, PSL: prednisolone, PTX: paclitaxel, PV: pemphigus vulgaris, RA: rheumatoid arthritis, UC: ulcerative colitis

In conclusion, KS can be seen in long-term steroid users even in the absence of HIV infection or transplantation. Steroids are the most widely used form of immunosuppressive therapy, and caution should be practiced in order to prevent the development of KS as an opportunistic infection. When patients on long-term steroid therapy present with overt GI bleeding and anemia, endoscopy with a biopsy seems to be essential for a definitive diagnosis.
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